Watson Pharmaceuticals, Inc. (WPI) -0.36

Trade WPI
NOW!
Last Trade:40.42Short Ratio:3.10
Last Trade Time:4:03pmDay Range:40.23 - 41.34
Ask:Year Range:27.45 - 42.50
Bid:One Year Target:43.42
Open:40.83Exchange:NYSE
Volume:1423682EBITDA:637.5M
Prev. Close:40.78Market Cap:4.993B
50 Day Moving:39.4186Div Yield:
200 day moving:37.8176PE:20.87

Watson to Present at Barclay's 2010 Global Healthcare Conference

Posted on 03/16/10 at 4:18pm
Watson to Present at Barclay's 2010 Global Healthcare Conference PR Newswire MORRISTOWN, N.J., March 16
Click here to read the rest of the article

Watson Pharma Climbing After Hours on Generic Hypertension Drug Approval (WPI)

Posted on 03/15/10 at 4:18pm
3/15/2010-Shares of Watson Pharmaceuticals (NYSE: WPI) are trading 1.3% higher to $40.82 after hours Monday after the company announced that its subsidiary, Watson Laboratories, Inc. - Florida, has received approval from the U.S.
Click here to read the rest of the article

Watson Receives FDA Approval for Generic Cardizem(R) LA

Posted on 03/15/10 at 4:09pm
Watson Receives FDA Approval for Generic Cardizem(R) LA PR Newswire MORRISTOWN, N.J., March 15
Click here to read the rest of the article

CORRECTING and REPLACING Columbia Laboratories Reports Fourth Quarter and Year End 2009 Financial Results

Posted on 03/11/10 at 10:39pm
LIVINGSTON, N.J.--(BUSINESS WIRE)-- In the table entitled "CONDENSED CONSOLIDATED BALANCE SHEETS," the figure for "Accumulated deficit" under December 31, 2009 should read: (256,979,263) (sted (56,979,263)). The corrected release reads:
Click here to read the rest of the article

FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer

Posted on 03/11/10 at 5:15pm
FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer - New formulation maintains mean testosterone levels similar to those achieved with surgical castration in just two doses each year -
Click here to read the rest of the article

Columbia Laboratories Reports Fourth Quarter and Year End 2009 Financial Results

Posted on 03/11/10 at 7:09am
LIVINGSTON, N.J.--(BUSINESS WIRE)-- Columbia Laboratories, Inc. (Nasdaq: CBRX) today reported financial results of the three- and twelve-months periods ended December 31, 2009. Fourth Quarter Highlights
Click here to read the rest of the article

Watson Announces Actos(R) Patent Challenge Settlement

Posted on 03/10/10 at 9:12am
Watson Announces Actos(R) Patent Challenge Settlement PR Newswire MORRISTOWN, N.J., March 10
Click here to read the rest of the article

Watson Confirms Filing of Generic Opana(R) ER Application

Posted on 03/08/10 at 5:39pm
Watson Confirms Filing of Generic Opana(R) ER Application - Patent Challenge Litigation Underway - PR Newswire MORRISTOWN, N.J., March 8
Click here to read the rest of the article

Watson Pharma Acquires Exclusive U.S. Rights to Columbia Labs's CRINONE and PROCHIEVE (WPI)

Posted on 03/04/10 at 8:27am
3/4/2010-Watson Pharmaceuticals (NYSE: WPI) announced Thursday it has agreed to acquire the exclusive U.S. rights to Columbia Laboratories, Inc.'s bioadhesive progesterone gel products currently marketed under the trade names CRINONE(R) and PROCHIEVE(R) for the indications of infertility and secondary amenorrhea.
Click here to read the rest of the article